Overview1
TAK-676 is a selective agonist of STimulator of INterferon Genes (STING), a critical molecule for initiating both innate and adaptive immunity via induction of type I interferon response
MOA2
STING signaling activated inflammation
Stimulator of INterferon Genes mediated Type I IFN response plays a core role in:
- Viral clearance
- Bacterial response
- Apoptosis of dying cells
STING signaling in cancer leads to two primary anti-tumors effects
- Activation of innate cells (macrophages, DCs) to produce IFN and “cross-primte” CD8 T cells and also activate NK cells that traffic to tumor
- Induction of tumor cell apoptosis (minor - in tumors with high STING)
Clinical Trials
Study Name
An Open-label, Dose Escalation, Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-676 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced or Metastatic Solid Tumors
CT.GOV ID
NCT04420884
Phase
Phase 1
Status
Recruiting
References
1. Takeda, Data on file.
2. O'Neill. Science. 2013.
Takeda Live Chat
Confirm Exit?
On exiting, all chat history will be cleared